Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Public ClinicalTrials.gov record NCT04551898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
Study identification
- NCT ID
- NCT04551898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2, 2020 (Actual)
- Primary completion
- May 25, 2021 (Actual)
- Completion
- May 25, 2021 (Actual)
- Last update posted
- Oct 26, 2024
2020 – 2021
United States locations
- U.S. sites
- 11
- U.S. states
- 3
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Btc Network Midland Florida Clinical Research Center | DeLand | Florida | 32720 | — |
| Elixia Clinical Research Collaborative | Hollywood | Florida | 33023 | — |
| Homestead Associates in Research Inc | Miami | Florida | 33032 | — |
| Medical Research Center of Miami Ii, Inc | Miami | Florida | 33134 | — |
| Us Associates in Research | Miami | Florida | 33175 | — |
| Continental Research Network | Miami | Florida | 33187 | — |
| Orlando Health Ufhealth Cancer Center | Orlando | Florida | 32806 | — |
| Revive Research Institute | Dearborn | Michigan | 48126 | — |
| Revival Research Institute Farmington Hills | Sterling Heights | Michigan | 48313 | — |
| Amarillo Center For Clinical Research | Amarillo | Texas | 79124 | — |
| Panamerican Clinical Research Us Headquarters | Brownsville | Texas | 78520 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04551898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2024 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04551898 live on ClinicalTrials.gov.